Total Funding
21
34
Total FundingDebt Financing raised
Growth Score 21 in past quarter
-38 pts
Heat Score 34 in past quarter
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
113915
Pulmotect develops an inhaled therapeutic designed to prevent and treat respiratory infections.
- Colin Broom: CEO
- Burton Dickey: Co-Founder
About the Company
Pulmotect is a biopharma company that develops products that boost the innate immune system to protect against a wide range of lung infections. Its technology stimulates the body’s natural defenses to provide safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror
agents (including anthrax, tularemia, and plague).
The company was founded in 2007 and is headquartered in Houston, Texas.